Nyrada has two lead drug development programs:

• A first-ever treatment to reduce secondary brain damage followingtraumatic brain injury (TBI) and stroke (Brain Injury Program).
• A cholesterol lowering drug that aims to reduce the risk of cardiovascular disease by delivering a cost-competitive and convenient oral cholesterol-lowering treatment to help achieve a targeted safe cholesterol level (Cholesterol Lowering Program).

Both programs target areas where there is a large unmet clinical need, where the current treatments are sub-optimal, or in the case of TBI, do not exist.

Further information in relation to these programs is available below: